Peijia Medical
Leo Tsai currently serves as the Chief Financial Officer at Peijia Medical (Suzhou) Co., Ltd since April 2019. Prior to this role, Leo held positions such as Director at Huatai Financial Holdings (Hong Kong) Limited and Vice President at Barclays Investment Bank, where responsibilities included investment banking within financial institution groups. Leo's extensive experience also includes being a Vice President at ICBC International, where notable transactions included IPOs for Huishang Bank and various debt offerings. Earlier in the career, Leo was involved in capital market deals and M&A transactions as an Associate at Citi and held positions at Cathay Financial Holdings and FRAMER INTERNATIONAL EXPORTING AND TRADING. Leo earned an MBA in Finance from Cornell Johnson Graduate School of Management and a Bachelor's in Business and Industrial Administration from National Taiwan University.
This person is not in any teams
Peijia Medical
Peijia Medical (HKEX: 9996), headquartered in Suzhou, China, is a leading medical device company dedicated to interventional solutions for structural heart and neurovascular diseases in China and globally. Established in 2012, Peijia Medical has long been committed to provide safe, effective and affordable solutions to improve patients’ quality of life through continuous innovations. We offer a complete portfolio of therapies to address aortic valve (Taurus Series), mitral valve and tricuspid valve replacement and repair, as well as neurovascular diseases related to brain ischemia and hemorrhage. 沛嘉医疗（港交所代码：9996）总部位于中国苏州，为中国乃至全球的结构性心脏病和脑血管介入领域提供解决方案。 沛嘉医疗成立于2012年，长期以来致力于通过持续的创新，为患者提供安全、有效、低成本的医疗方案，提升患者生活质量。我们拥有完整的产品治疗管线，包括主动脉瓣（Taurus系列产品）、二尖瓣和三尖瓣的置换和修复产品，以及与缺血性和出血性相关的脑血管疾病介入产品。